Abbott Laboratories Inc. ’s Absorb everolimus-eluting bioresorbable vascular scaffold(BVS) remains on track for a late-2015 PMA submission based on data showing the novel device performed at least as well as the company’s Xience everolimus-eluting metal stent at the one-year follow-up of the first randomized controlled trial for the dissolving coronary stent.
One-year results from 501 patients in the ABSORB II